Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy
This study includes patients 16 years of age or older with a confident diagnosis of epilepsy who are currently treated with an antiepileptic drug (AED) monotherapy but require a change in therapy due to inadequate seizure control and/or unacceptable side effects.
|Study Design:||Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Multicenter, Open-Label Conversion of Valproate Monotherapy to Lamotrigine Monotherapy in Patients With Epilepsy|
- Drug levels of lamotrigine.
- This study has no secondary outcome measures.
|Study Start Date:||January 2002|
|Study Completion Date:||January 2003|
|Primary Completion Date:||January 2003 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00043914
Show 24 Study Locations
|Study Director:||GSK Clinical Trial, MD||GlaxoSmithKline|